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TGF-β concentrations and activity 
are down-regulated in the aqueous 
humor of patients with neovascular 
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Controversy still exists regarding the role of the TGF-β in neovascular age-related macular degeneration 
(nAMD), a major cause of severe visual loss in the elderly in developed countries. Here, we measured 
the concentrations of active TGF-β1, TGF-β2, and TGF-β3 by ELISA in the aqueous humor of 20 patients 
affected by nAMD, who received 3 consecutive monthly intravitreal injections of anti-VEGF-A antibody. 
Samples were collected at baseline (before the first injection), month 1 (before the second injection), 
and month 2 (before the third injection). The same samples were used in a luciferase-based reporter 
assay to test the TGF-β pathway activation. Active TGF-β1 concentrations in the aqueous humor were 
below the minimum detectable dose. Active TGF-β2 concentrations were significantly lower at baseline 
and at month 1, compared to controls. No significant differences in active TGF-β3 concentration were 
found among the sample groups. Moreover, TGF-β pathway activation was significantly lower at 
baseline compared to controls. Our data corroborate an anti-angiogenic role for TGF-β2 in nAMD. This 
should be considered from the perspective of a therapy using TGF-β inhibitors.
Age-related macular degeneration (AMD) is a major cause of visual loss among the elderly in developed coun-
tries. Neovascular AMD (nAMD), a subtype of advanced AMD, is responsible for almost 90% of severe visual 
loss due to AMD1. Many growth factors have been implicated in the pathogenesis of nAMD, with a prominent 
role being played by vascular endothelial growth factor A (VEGF-A)2. Transforming growth factor beta (TGF-β) 
has also been studied extensively. The TGF-β family consists of a group of three isoforms, TGF-β1, TGF-β2, and 
TGF-β3, with redundant functions. TGF-β is secreted in a latent (not biologically active) form and is unable to 
bind to receptors. Before TGF-β can exert its biological effects, it needs to be activated by being released from 
the complex with latency-associated peptide (LAP) and latent transforming growth factor-beta binding protein 
(LTBP)3. Active TGF-β binds specific transmembrane Ser/Thr kinase receptors, which in turn transduce the sig-
nal by phosphorylating the receptor-regulated (R-) SMAD2/3 transcription factors.
Controversy still exists regarding the role of the TGF-β family members in choroidal neovascularization 
(CNV), since they have a pleiotropic effect and may play different roles in the regulation of vascular endothelial 
and smooth muscle cells, being either anti- or pro-angiogenic in a context-dependent way4,5. In the eye, TGF-β 
has been shown to act as an anti-angiogenic factor6 and to protect retinal pigment epithelium (RPE) cells and 
retinal vasculature7–10. However, other findings suggest it has a pro-angiogenic effect in the eye: TGF-β not only 
induces VEGF-A expression by RPE11, but its direct and indirect inhibition has also been linked to the inhibition 
of both the epithelial-mesenchymal transition and senescence of RPE cells in vitro12–15, as well as to the blockage 
of CNV16–18, including the subretinal fibrosis stage19,20, in animal models. In humans an increased expression 
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of TGF-β has been documented in surgically removed CNV tissue21, while an increased concentration of total 
TGF-β1 has been found in the vitreous18 and aqueous humor22 of nAMD patients. Thus, in accordance with the 
possible role of TGF-β in favoring CNV, its treatment with TGF-β blocking agents has been advocated16–20.
However, knowledge in this field is still limited, since the vast majority of the above-mentioned studies 
(regarding both anti- and pro-angiogenic aspects) have been conducted in vitro or in animals, and rarely consider 
all the TGF-β isoforms simultaneously. In fact, in addition to TGF-β1, TGF-β2, which is presumed to be the pre-
dominant isoform in the eye15,19,23, and TGF-β3 might deserve attention in the context of nAMD, where they have 
not been measured yet. Moreover, measurement of the total TGF-β1 protein concentration in the biological fluid 
of human eyes, as previously conducted by our group22 and by Bay et al.18, might only partially reflect the effective 
concentration of the active form.
In the present study we evaluated the protein concentration of active TGF-β1, TGF-β2, and TGF-β3 in the 
aqueous humor of patients affected by naïve nAMD, at baseline and after intravitreal anti-VEGF-A injection. 
Moreover, we set up a luciferase-based reporter assay to test the TGF-β pathway activation by aqueous humor 
samples.
Results
Assessment of active TGF-β1, β2 and β3 levels in aqueous humor. The study measured the lev-
els of active TGF-β1, β2 and β3 in the aqueous humor of 20 patients with nAMD, who received 3 consecutive 
monthly intravitreal injections of anti-VEGF-A antibody (0.5 mg ranibizumab). Samples were collected at base-
line (before the first injection), month 1 (before the second injection), and month 2 (before the third injection). 
20 age-matched cataract patients served as controls. The demographic data and patient characteristics are stated 
in Table 1. Concentrations of active TGF-βs were measured by ELISA. Active TGF-β2 and β3 were detected and 
quantified both in controls and in patients, while the active TGF-β1 concentration was below the minimum 
detectable dose (5 pg/ml) for the majority of the samples analyzed (data not shown).
In controls, the aqueous humor concentration of active TGF-β revealed the preponderance of TGF-β2 over 
TGF-β3 and, to a greater extent, over TGF-β1. In particular, from total active TGF-β, 70% was TGF-β2, 28.5% 
was TGF-β3 and less than 1.6% was TGF-β1, thus suggesting an important role of TGF-β2 and TGF-β3 in the 
homeostasis of the eye (Fig. 1).
The comparison of active TGF-β2 and TGF-β3 concentrations between patients and controls, revealed 
that baseline (naïve AMD) and month 1 (Treat.1) concentrations of active TGF-β2 were lower than in controls 
(controls mean ± SD = 214.2 ± 90.37 pg/mL; baseline AMD mean = 151.4 ± 63.6 pg/mL; month 1 mean = 
 157.3 ± 71.0 pg/mL), while the month 2 (Treat.2) value was lower, albeit not significantly, than the control value 
(month 2 mean = 170.7 ± 60.2 pg/mL) (Fig. 2a). The baseline, month 1and month 2 active TGF-β3 concentrations 
did not differ from controls (controls mean ± SD = 87.5 ± 30.05 pg/mL; baseline mean ± SD = 85.5 ± 39.65 pg/mL; 
month 1 mean ± SD = 78.6 ± 20.23 pg/mL; month 2 mean ± SD = 73.4 ± 29.61 pg/mL] (Fig. 2b). Additionally, 
summing the concentrations of active TGF-β2 and TGF-β3 for every single sample, we found that the base-
line and month 1 total active TGF-β2/β3 concentration was still significantly lower compared to the con-
trol group (controls mean ± SD = 301.8 ± 92.9 pg/mL; baseline AMD mean = 236.9 ± 76.9 pg/mL; month 1 
mean ± SD = 235.8 ± 75.1 pg/mL) while month 2 values were slightly, but not significantly, lower than in the con-
trol group (month 2 mean ± SD = 244.1 ± 64.73 pg/mL) (Fig. 3).
Analysis of TGF-β pathway activation. The TGF-β superfamily includes, besides TGF-βs, a large group 
of proteins (BMPs, GFDs, activins, etc) and its signaling is regulated by soluble binding proteins such as Alpha-
2-Macroglobulin, Follistatin and Decorin24. Therefore, to measure the effective TGF-β pathway activation, we set 
up a Luciferase-based reporter assay using Lenti-X 293T cells transfected with a plasmid carrying the NanoLuc® 
gene under the transcriptional control of three copies of the SMAD binding element (SBE) specific for SMAD325. 
A plasmid for Firefly (luc2) Luciferase expression under the control of the constitutive HSV-TK promoter was 
also co-transfected as transfection normalizer. The Lenti-X 293T cell line was chosen because it responds to 
TGF-β stimulation, grows densely and is easy to efficiently transfect, permitting the setup of a sensitive method 
for measuring TGF-β activity. The transfected cells were treated with 10 μl of aqueous humor of the 20 nAMD 
patients, naïve or treated, or of the 20 control samples. After 3 hours Firefly and NanoLuc luciferase activities were 
measured for each sample. We measured a significant reduction in luciferase activity in the cells treated with naïve 
nAMD Group, n = 20 Control Group, n = 20 P value
Age (years) 77.5 ± 10.25 77.65 ± 8.68 0.578#
Sex (male/female) 1:0.67 0.82:1 0.342§
Eyes (n) 20 20 N/A
Type of choroidal neovascularization (n) 16 type 14 type 2 N/A N/A
Central Retinal Thickness day 0 (μm) 306.45 ± 57.78 N/A N/A
Central Retinal Thickness after 3 treatments (μm) 239.45 ± 33.85 N/A N/A
Neovascular lesion size (μm) 1971.25 ± 1021.02 N/A N/A
Table 1. Comparison of nAMD patients and control group, with patients’ clinical characteristics. Age, retinal 
thickness and lesion size are expressed as mean ± standard deviation. N/A: not applicable. #Mann-Whitney U 
test. §Chi-squared test.
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nAMD samples compared to control samples. In the aqueous humor of the ranibizumab-treated patients, the 
control level was restored after the first injection (Fig. 4). Although we did not observe a significant correlation 
between active TGF-β2 concentration and luciferase activity (Fig. 5), we found a significant correlation between 
the luciferase activity and the sum of the concentrations of active TGF-β2 and TGF-β3 for every single sample in 
both control and naïve nAMD specimens (Fig. 6a and b), but not in ranibizumab treated patients, both after the 
first and the second injection (Fig. 6c and d). To evaluate whether lower TGF-β levels in aqueous humor samples 
of nAMD patients correspond to a down-regulation of the TGF-β pathway activation in choroidal neovascular 
membranes, we analyzed by immunofluorescence staining the presence of phospho-SMAD2 in endothelial cells 
(ECs) of normal choroid and choroidal neovascular membranes (CNVMs) obtained from two additional naïve 
nAMD patients during submacular surgery. As shown in Fig. 7, we observed the phosphorylation of serines 465 
and 467 of SMAD2 in ECs of normal choroidal vessels but not of CNVMs from naïve nAMD patients.
Figure 1. Pie chart of TGF-β1, TGF-β2 and TGF-β3 concentrations in the aqueous humor of a sample group 
of 20 healthy subjects. The concentration of active TGF-β1, β2 and β3 was measured by ELISA. The mean of the 
total concentration of all TGF-βs, the percentage of the total, and the mean ± SD of each isoform are shown. 
Each sample was measured twice for TGF-β2 and TGF-β3 and once for TGF-β1.
Figure 2. ELISA analysis of the aqueous levels of TGF-β2 and TGF-β3. The TGF-β2 (a) and TGF-β3 (b) protein 
concentrations in the aqueous humor of 20 patients and 20 controls (described in Table 1) were determined 
by ELISA. Each sample was measured twice. Data are presented as box and whisker plots displaying the 
median, lower, and upper quartiles (boxes) and minimum-maximum (whiskers). Asterisks indicate significant 
differences (*P < 0.05) between naïve or treated (once or twice, Treat.1 and Treat.2, respectively) patient groups 
and the control group (Cntr.).
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Discussion
Controversy still exists regarding the role of the TGF-β family and its pathway in nAMD. Studies on humans are 
needed since most of the conflicting evidence comes from in vitro or animal studies, which have mainly addressed 
TGF-β1 and only rarely TGF-β2 and TGF-β32,6–11. Moreover, since the TGF-β isoforms are secreted in their latent 
Figure 3. Box and whisker plot showing the sum of TGF-β2 and TGF-β3 concentrations for every single sample 
(derived from dataset of Fig. 2). Data are presented as box and whisker plots displaying the median, lower, 
and upper quartiles (boxes) and minimum-maximum (whiskers). Asterisks indicate significant differences 
(*P < 0.05) between naïve or treated (once or twice, Treat.1 and Treat.2, respectively) patient groups and the 
control group (Cntr.).
Figure 4. Quantitative analysis of TGF-β pathway activation by aqueous humor of patients and controls. 
Box and whisker plot showing that the aqueous humor of naïve nAMD patients induces less TGF-β pathway 
activation in Lenti-X 293T cells. Cells were co-transfected with the plasmids pNL[NlucP/SBE], expressing 
NanoLuc luciferase under the control of three SMAD3 binding elements, and pGL4.54[luc2/TK], expressing the 
Firefly luciferase luc2 (used as transfection normalizer) under the control of the constitutive HSV-TK promoter. 
Transfected cells were treated with 10 μl of aqueous humor of the 20 nAMD patients, naïve or treated (once 
or twice, Treat.1 and Treat.2, respectively), or of the 20 control samples (Cntr.) described in Table 1. Data are 
presented as the ratio between NanoLuc and luc2 luciferase activity, expressed as Relative Light Units (RLU) 
(number of replicates for each sample = 3). Asterisks indicate significant differences (**P < 0.01) between naïve 
or treated (once or twice, Treat.1 and Treat.2, respectively) patient groups and the control group (Cntr.).
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form, measurements of their total concentration, as performed in previous human studies, may not necessarily 
be equivalent to measurements of the active isoforms.
TGF-β1 is the most extensively studied isoform both in in vitro and in vivo, since it has been found to target 
the vascular endothelium in normal physiological circumstances to a greater extent than TGF-β2, and to be the 
isoform most expressed in ECs during embryogenesis3,26. Additionally, TGF-β1 has been found to be overex-
pressed in surgically excised CNV membranes21. However, TGF-β2 represents the preponderant isoform in the 
eye15,19,23 and TGF-β2 knockout mice present severe ocular anomalies in the retina, cornea and the lens23, thus 
postulating the isoform’s active involvement in the maintenance of physiological ocular status. Extensive studies 
in the skin have revealed a role for TGF-β2 and β3 in non-scarring wound healing. Furthermore, it was shown 
that changes in the ratio between the three isoforms can determine the final anatomical status after inflamma-
tion27,28. Moreover, although TGF-β1, β2 and β3 derive from different genes, functional redundancy may occur3.
The present study analyzes the aqueous humor concentrations of active TGF-β1, β2 and β3 at baseline and 
after 1 and 2 intravitreal injections of ranibizumab in previously untreated patients affected by nAMD. The same 
measurements were performed on controls. In controls, the aqueous humor concentration revealed the prepon-
derance of TGF-β2 over TGF-β3 and, to a greater extent, over TGF-β1, thus suggesting a main role for TGF-β2 
in the homeostasis of the eye under physiological conditions. This was confirmed under pathological conditions 
by the lower TGF-β2 concentration measured in nAMD patients at baseline and after injections in compari-
son to controls (although the difference was not significant at month 2), while the TGF-β3 concentration was 
unchanged. Considering the total concentration of both these two isoforms in each of the patients, we obtained 
a trend similar to that of TGF-β2 concentration alone, with the baseline concentration still significantly lower 
compared to the control group. This shows that the preponderant TGF-β2 has an important effect on the final 
total concentration and could suggest a protective effect of TGF-β2 on nAMD. In accordance with our results, 
Yafai and colleagues showed a Müller cell-guided inhibition of retinal ECs proliferation via TGF-β229. On the 
contrary, in animal models, Zhang et al. showed that the inhibition of TGF-β20 and the antagonism of COX-219, 
with the consequent down-regulation of TGF-β2, attenuated subretinal fibrosis after CNV induction. However, 
the subretinal fibrosis stage in their CNV animal model can hardly be compared to our findings regarding the 
first stage of CNV in humans. In accordance with Zhang et al.19,20. Recalde and colleagues showed a reduction 
of diode-laser-induced CNV in rats following use of two peptides anti-TGF-β, including TGF-β217. However, 
the laser-induced CNV animal model is characterized by an acute injury and inflammation, representing only 
Figure 5. Correlation analysis of TGF-β2 concentrations in the aqueous humor and luciferase activity. Data 
are presented as scatter plots. No correlation was found between the concentrations of TGF-β2 and SMAD2/3 
activation, expressed as luciferase activity. The significance of correlations was tested using Spearman rank-
order correlation coefficient (r). P (two-tailed) values are indicated.
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the neovascular component of the disease, and consequently is unable to recapitulate the complex sequence of 
events leading to the development of CNV in patients with nAMD, such as long-term senescent degeneration and 
chronic inflammation.
We measured TGF-β in the active form but, since the TGF-β pathway is context-specific and potentially 
influenced by many factors, we also wanted to verify whether there was a correlation between the concentra-
tions of the active isoforms and the activity of the pathway. The TGF-β pathway is complex. The three isoforms, 
together with the other superfamily members, such as the Bone Morphogenetic Proteins (BMP), can interact 
with two types of receptors (ALK5 and ALK1) and two types of coreceptors (endoglin and betaglycan), leading 
Figure 6. Correlation analysis of total TGF-β2/β3 concentrations in the aqueous humor and luciferase 
activity. Data are presented as scatter plots. In controls (a) and naïve AMD patients (b), a correlation was found 
between the concentrations of total TGF-β2/β3 and SMAD2/3 activation, expressed as luciferase activity. The 
significance of correlations was tested using Spearman rank-order correlation coefficient (r). P (two-tailed) 
values are indicated. No correlation was found in the treated sample groups (c,d).
Figure 7. Phospho-SMAD2 (Ser465/467) (P-SMAD2) is detected in the nuclei of ECs of normal choroidal 
blood vessels but not in ECs of the CNVMs of AMD patients. Fixed paraffin-embedded CNVM sections 
from 2 AMD patients and human eye sections containing normal choroidal blood vessels were analyzed 
by immunofluorescence using phospho-SMAD2 (green) and CD34 (red) antibodies. Arrowheads indicate 
P-SMAD2 positive nuclei. Arrows and asterisks indicate the retinal pigment epithelium and red blood cells, 
respectively, which exhibits autofluorescence. Scale bars, 14 μm.
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to the phosphorylation of SMAD2 and 3 - the anti-angiogenic TGF-β/ALK5 pathway - or of SMAD1, 5 and 
8 - the proangiogenic TGF-β/ALK1 pathway3,4,26. Endoglin seems to play a role in the activation of the ALK1 
pro-angiogenic pathway in the presence not only of BMP but also of TGF-β1 and β33,4,26. However, TGF-β1 
and 3 can also activate the ALK5/SMAD2 and 3 pathway (the canonical most-studied pathway), leading to an 
anti-angiogenic effect3,4,26. In contrast, TGF-β2 associates with coreceptor betaglycan activating anti-angiogenic 
ALK5/SMAD2/3 signaling30–32. Here, we observed a decrease in SMAD2/3 pathway activation by the aque-
ous humor of nAMD patients, suggesting a possible down-regulation of the anti-angiogenic TGF-β pathway 
in nAMD, as also supported by the immunofluorescence data in choroidal ECs. Since in the same patients, 
we observed a lower TGF-β2 concentration compared to controls, we would have expected a correlation (in 
each patient) between TGF-β2 concentrations and the decreased SMAD2/3 pathway activation. Surprisingly, 
SMAD2/3 pathway activation did not correlate with TGF-β2 concentration, but did correlate with the sum of the 
concentrations of active TGF-β2 and TGF-β3. This suggests that the effect on the TGF-β pathway activation is 
mediated by the combined action of TGF-β2 and TGF-β3, although only TGF-β2 was down-modulated in nAMD 
group and consequently could be involved in pathophysiology of nAMD. This correlation was observed in both 
controls and patients at baseline, but was not apparent after treatment. This may be explained by the cross-talk 
between the VEGF-A and TGF-β signaling pathways, although not yet completely elucidated4,33. Ranibizumab 
might also change the aqueous molecular constitution via VEGF-A antagonism, thus rendering such a TGF-β 
pathway less directly dependent on TGF-β levels.
Inhibition of the TGF-β pathway has been advocated as an additional treatment option in the battle against 
nAMD. In light of our results, which suggest a protective role of TGF-β2 in nAMD, a general inhibition of TGF-β 
should be viewed with caution, and more specific target should be considered2. However, further independent 
studies are needed to confirm this issue using a larger number of samples and to better understand the functional 
consequences of different levels of TGF-β pathway activation in nAMD and the distribution of the TGF-β iso-
forms in the different eye compartments and tissues.
Methods
Subjects. This observational case-control study comprised 20 patients affected by active nCNV secondary 
to AMD. All eyes were examined and treated between June 2016 and December 2016 at the Ophthalmology 
Unit of the Department of Medicine, Surgery and Neuroscience, Siena University Hospital, Siena, Italy, following 
approval from the institutional review board. The study complied with the Declaration of Helsinki and was reg-
istered in the ISRCTN registry (reference number: ISRCTN60434145; date of registration: 12/01/2018). Patients 
were treated after being informed of the nature, purpose, implications and risks of the treatment and after having 
signed a consent form.
The study enrolled patients who presented with CNV secondary to AMD. The diagnosis was confirmed by 
fluorescein angiography (FA), indocyanine green angiography (ICGA) and spectral domain optical coherence 
tomography (OCT).
Patient demographics, study eye characteristics and treatment details were recorded, including: best corrected 
visual acuity (BCVA) at baseline and during the course of follow up, measured using ETDRS charts at a distance 
of 4 m; CNV subtype; lesion size, determined by the greatest linear dimension measured by fluorescein angiog-
raphy examination prior to treatment; and central macular thickness (CMT) at baseline and each follow up visit.
None of the patients had received any previous treatment for nAMD, nor had they undergone any previous 
ophthalmic surgery, except cataract removal. Cataract surgery had to have been performed at least 9 months 
prior to inclusion. Controls were age-matched patients undergoing cataract surgery. The exclusion criteria for 
controls were any ocular disease other than cataracts and any previous ophthalmic surgery. Diabetes mellitus, 
use of immunosuppressive drugs and a malignant tumor in any location constituted exclusion criteria for both 
patients and controls.
Aqueous humor sample collection. All patients with nAMD received 3 consecutive monthly intravitreal 
injections of anti-VEGF-A therapy (ranibizumab 0.5 mg). Aqueous samples were collected prior to injections at 
baseline (day of the first injection), month 1 (day of the second injection), and month 2 (day of the third injection).
Anterior chamber taps were performed in the operating room prior to each intravitreal injection (patients) 
and before cataract surgery (controls). A 30-gauge needle was inserted into the anterior chamber and 0.16–0.2 mL 
of aqueous was collected, centrifuged at 1500 g for 20 minutes to remove cells and debris, aliquoted and frozen at 
−80 °C until analysis.
Assessment of active TGF-β1, β2 and β3 levels in aqueous humor. The concentration of active 
TGF-β1, β2 and β3 in the aqueous humor was measured by enzyme-linked immunosorbent assay (ELISA) using 
ELISA kits for human TGF-β1, TGF-β2 (Quantikine ELISA kits #DB100B and #DB250, respectively; R&D 
Systems, Minneapolis, USA) and TGF-β3 (#SEB949Hu; Cloud-Clone Corp., Houston, TX). Each assay was per-
formed according to the manufacturer’s instructions without the acidification step for activation of latent TGF-β, 
allowing the detection of the active forms. For each measurement of TGF-β concentration, 25 μl of sample were 
diluted to 100 μl using sample diluent buffer immediately prior to the assay. Each sample was measured twice for 
TGF-β2 and TGF-β3. Each sample was measured once for TGF-β1, after a preliminary analysis on extra-groups 
specimens showing that the active TGF-β1 concentration was below the minimum detectable dose (5 pg/ml).
Analysis of TGF-β pathway activation. The luciferase-based reporter system used to analyze activa-
tion of the TGF-β pathway consisted of Lenti-X 293T cells (#632180; Takara Bio, CA) transiently transfected 
with the plasmid pNL[NlucP/SBE] (Promega Corp., Madison, WI), carrying three copies of the SMAD binding 
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element (SBE) (AGTATGTCTAGACTGA) which represent specific targets of for phospho-SMAD325 and drive 
the expression of a reporter gene encoding NanoLuc® Luciferase. The plasmid pGL4.54[luc2/TK] (Promega 
Corp., Madison, WI), carrying the reporter luc2 gene coding firefly luciferase under the control of the con-
stitutive HSV-TK promoter, was co-transfected with pNL[NlucP/SBE] at a molar ratio of 5:1 (pGL4.54[luc2/
TK]:pNL[NlucP/SBE]) as a normalizer for transfection efficiency. Cells were grown as previously described34 and 
transfected in suspension using Attractene Transfection reagent (#301005; Qiagen, Hilden, Germany) following 
the manufacturer’s instructions, then plated (2 × 104 cells/well) on 96-well plates. After 24 hours cells were treated 
with 10 μl of aqueous humor for 3 hours. Cells were then lysed in 100 μl Passive Lysis Buffer and subsequently 20 μl 
of the lysate was assayed using the Nano-Glo® Dual-Luciferase® Reporter Assay System (#N1610; Promega Corp., 
Madison, WI). Luciferase activity was read using TD20/20 luminometer (Turner Diagnostics, Sunnyvale, CA) and 
expressed as relative luminescence units (RLU). Normalization of transfection efficiency was obtained dividing 
RLU from NanoLuc® readings by RLU from luc2 readings. Three replicates were performed for each sample.
Immunofluorescence. CNVMs were collected from naïve nAMD patients during submacular surgery 
as previously described35. Normal choroid sections were obtained from 2 eyes enucleated for retinoblastoma35. 
Specimens were incubated with rabbit polyclonal anti-phospho-Smad2 (Ser465/467) (#AB3849; Chemicon 
International/Millipore, Billerica, MA) and mouse monoclonal anti-CD34 (#QBEnd/10; Ventana Medical 
Systems, Inc., Strasbourg, France) as EC marker. Alexa Fluor-488 or 568 (Thermo Fisher Scientific, Waltham, 
MA) secondary antibodies were used. Fluorescent images were captured using a Leica TCS SP2 laser-scanning 
confocal microscope.
Statistical analysis. The data analysis was performed using Prism 6 statistical software (GraphPad Software 
Inc., San Diego, CA). Data are presented as box and whisker plots displaying the median, lower and upper quar-
tiles and the minimum-maximum. Data normality was tested using D’Agostino and Pearson omnibus normality 
test. Evaluation of the data was conducted using one-way ANOVA, followed by Bonferroni multiple comparison 
post-hoc test. The significance of correlations between protein concentrations in the aqueous humor and normalized 
luminescence was tested using Spearman rank-order correlation coefficient (r). P (two-tailed) values are indicated.
Data Availability. The datasets generated during the current study are available from the corresponding 
author on reasonable request.
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